← FDA DRUG APPROVALS

FDA ANDA · ANDA219983

SACUBITRIL AND VALSARTAN

Sponsor: SOMERSET THERAPS LLC

APPLICATION
ANDA219983
TYPE
ANDA
ORIGINAL APPROVAL
2026-01-20
LATEST ACTION
2026-01-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SACUBITRIL AND VALSARTANPrescription
SACUBITRIL 49MG, VALSARTAN 51MG · TABLET · ORAL
SACUBITRIL AND VALSARTANPrescription
SACUBITRIL 97MG, VALSARTAN 103MG · TABLET · ORAL
SACUBITRIL AND VALSARTANPrescription
SACUBITRIL 24MG, VALSARTAN 26MG · TABLET · ORAL

Approval history

2026-01-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →